mtlurb

Oui exactement deux pays différents, deux politiciens aux opposés... mais les médias à gauche aiment ça tout "étiqueter" Trump ou extrême droite... dès que c'est pas à gauche. lol Il entends couper la majorité des ministères et leur employés... c'est peut être impossible pour '24, mais il sera pas très loin. Coupe Ia banque centrale, c'est comme détruire la machine à imprimer le cash... ce que les gouvernements argentins des dernières 80 années ont abusés... bref, c'est difficile pour nous de comprendre leur situation puisqu'au Canada et USA, les banques centraux sont "très" indépendantes. Je sais que Milton Fridman avait conseillé le Chili en mettant en place des mesures similaires dans les années 70-80, mais moins draconiennes, et ça été un franc succès.... jusqu'à ce que le dernier gouvernement tue la poule aux oeufs d'or.

Un petit vidéo pour décortiquer les grandes différences entre Trump et le nouveau président argentin Milei.

Zibi = 🍆 dans une autre langue 🤣

Ampute la voie pour bus... les bus n'auront plus besoin de passer le pont? Où je me trompes.

Nationaliser le CN c'est 104 milliards de dollars à la valeur du marché... À moins que le journaliste sous-entendais de prendre ça gratis comme dans une vraie république de banane.

😜

Montreal family wants apology from city after video shows snow plow striking cars Voir la video: https://globalnews.ca/news/10159910/montreal-snow-plow-cars-hit/

AI-based drug developer Insilico starts seriously staffing up in Montreal December 11 at 1:45 AM By David Reevely Forty slides into his presentation on generative AI in the pharmaceutical business, Alex Zhavoronkov’s staff are trying to give him the hook. He has been going about his task, celebrating the expansion of Insilico Medicine’s offices in Montreal in an unorthodox way. “I’m going to need another 16 minutes, max,” he says to someone off stage. “Can I do that? What do you mean, ‘No, no’?’” B ut Zhavoronkov is Insilico’s founder and co-CEO, which makes this gathering in the Queen Elizabeth Hotel his party, and him the black-clad, Slavic-accented, slick-haired master of ceremonies on a riser. Fine, he says. I have 20 slides left, but I’ll skip a few and go fast. Buckle up. Talking Points Insilico Medicine’s Alex Zhavoronkov says he refuses to engage in geopolitics, but the AI-based drug company is staffing up in Montreal because of tectonic political and economic forces Insilico’s Eastern European data scientists mostly moved to the Persian Gulf in 2022, where they’re overseen by a Concordia PhD and see some of the results of their work tested in wet labs in China for a company with headquarters in Hong Kong and New York It’s not as though Zhavoronkov’s audience can’t appreciate the ride, even if it is sometimes a fever of logos and dense timelines and imaging methylation transcriptomics. The group includes people like Health Canada’s chief data officer, and its director general for rare diseases; senior officials from Innovation Canada; whizzes like the University of Toronto’s Alán Aspuru-Guzik and Steve Liu, a McGill University professor and associate member of Mila, Montreal’s AI research institute. Also Stéphane Paquet, the CEO of the investment promotion agency Montréal International, who is tickled to have landed the Insilico expansion. “I must say that we’ve had quite a few AI labs in recent years,” Paquet says. But this one “merges two of the most strategic sectors in Montreal, which is life sciences and AI.” It didn’t have to be in Montreal. Founded in the U.S. in 2014, Insilico now feels like a throwback to peak globalization, scattered around the world with a globetrotting chief executive (whose languages don’t include French). The company’s twin headquarters are in New York and Hong Kong. Its key AI researchers are mainly in the United Arab Emirates, and most of its wet-lab work in mainland China. Zhavoronkov is a Latvian Canadian (born Aleksandrs Žavoronkovs) with degrees from Queen’s in Kingston, Ont., Johns Hopkins in Baltimore, Md., and Lomonosov Moscow State University. Zhavoronkov’s mission, through Insilico, is to solve aging. If he can’t do that, he wants to extend people’s lives as much as he can and “ensure that the transition from today to the grave is as pleasant as possible, and disease-free.” That’s the goal. Insilico’s method is to, in Zhavoronkov’s words, “deliver really effective therapeutics to patients at record speed.” The process of taking a drug from concept to market is so arduous, he says, that he can address a room full of professional pharma researchers and be speaking to nobody who has actually done it. Pulling it off takes years and sometimes billions of dollars. “It’s a very rare skill set. With AI, those people who have the skill set—they can become superheroes,” he says. Insilico has no drugs on the market yet, but it has several in clinical trials and others in pre-clinical testing. Clinical trials to prove that a new medicine is safe, effective and worth the costs and side effects are necessarily arduous and time-consuming, and AI-aided drug discovery is new. The company already has a presence in Montreal, built around Petrina Kamya. A Concordia chemistry PhD originally from Nairobi, Kamya is the president of Insilico Canada and the global head of Insilico’s AI platform work. “A year and a half ago, it was just me, as the employee in Canada,” she said in an interview. “Having been educated in Montreal, I’ve seen a lot of my classmates come and leave. … It was always one of my passions to bring those people back.” “I object to any form of racism or nationalism, and support globalization and cooperation, which was kind of the spirit of Canada when I first arrived.” Kamya herself joined Insilico almost by chance, encountering Zhavoronkov while she was doing due-diligence work for investment banks interested in the drug business. He convinced her to join the company early in the COVID-19 pandemic. “We did not see each other in person for the first two years,” Zhavoronkov told The Logic in an email exchange. Home for him is sort of Abu Dhabi, sort of Hong Kong, but really anywhere he can get Wi-Fi. “I … refuse to engage in any kind of geopolitics, object to any form of racism or nationalism, and support globalization and cooperation, which was kind of the spirit of Canada when I first arrived in 1996,” Zhavoronkov wrote. Geopolitics, however, engages with Insilico. Zhavoronkov returned to Baltimore to start the company, but found deep-learning professionals in the U.S. scarce, and their salaries prohibitively expensive. “I outsourced many of the algorithmic tasks to Russia, Ukraine and Poland,” Zhavoronkov wrote. When Russia invaded Ukraine in 2022, that arrangement became untenable, but bringing most of the team from Eastern Europe to Canada—through an overburdened immigration system that favours the most highly skilled applicants—was impractical. “Anyone who’s junior, you’d have to go through a very, very long process,” Kamya said. The U.A.E. welcomed those people more eagerly, so that’s where most of them went. The result was a group of 13 leaders with Kamya in Montreal, overseeing teams totalling about 80 people located halfway around the world on the Persian Gulf. “The idea of what we have planned for Montreal is to take advantage of [local] talent. So we have the office now established, and the idea is to grow the team in Montreal,” she said. The company has approached its landlord in its downtown office tower—1250 René-Lévesque Blvd. W., one of the most prominent in the city—about renting more space. Insilico has three AI-based tools to help find new drugs: PandaOmics for identifying chemical structures to target, Chemistry42 for identifying chemicals that could target them, and inClinico to help design clinical trials to test whether they work. It’s now bound them together with a ChatGPT-based interface, to make configuring their highly specialized features simpler by, for instance, translating a quality like “better at crossing the blood-brain barrier” into precise parameters. It is not only a tools company: Insilico is working on drugs of its own, with four candidates in clinical trials. One, a treatment for idiopathic pulmonary fibrosis, a degenerative lung condition, has reached the stage of recruiting patients in China for Phase 2 trials, and Insilico has registered plans with the Food and Drug Administration to conduct U.S. trials. Even a Phase 2 trial is a long way from the market, but it puts Insilico’s drug among the most successful AI-derived pharmaceuticals yet. “Initially, we were a tech-first company. We were developing the tools. And we were constantly asked, ‘How do we know it works?’” Kamya said. “So we decided to build our own pipeline to show that if we can do it as a small tech company, and get to the clinic faster and cheaper, then any of our partners or people who can leverage our technology can also do that.” To the obvious question this raises—why sell access to the tools if Insilico can make drugs itself?—Kamya answered that making and testing real-world drugs is expensive, and licensing the underlying technology makes money now. “If you do your synthesis and test [in China], you can get drugs to patients one year sooner, with higher probability of success.” What’s more, getting to human trials requires an enormous amount of pre-clinical laboratory work. Geopolitics again. Canada has stomped on federally funded academic partnerships with potential adversaries—with both artificial intelligence and biotechnology on its preliminary list of sensitive research areas. But as a private company, Insilico isn’t directly bound by those restrictions, so it can assign lab work to specialty contractors in China. “China built the most efficient contract research infrastructure on the planet,” Zhavoronkov told The Logic. “According to my estimates, if you do your synthesis and test there, you can get the drugs to patients at least one year sooner and with higher probability of success.” The research work is contracted out but overseen by Insilico scientists, Zhavoronkov wrote. “Our lab works with cells, organoids, and animal tissues, disease models, and xenografts, but we do not process any patient data. We rely on local vendors to process biological data and also to conduct clinical trials.” The China connection extends beyond contract research. Warburg Pincus led investment in Insilico’s US$255-million Series C round in 2021, which included participation from China’s Qiming Venture Partners, Sinovation Ventures and Baidu Ventures, plus trans-Pacific entities like Pavilion Capital, Lilly Asia Ventures and Sequoia Capital China. “PandaOmics,” the AI tool for finding potential drug targets, is a rebranding of a platform previously named “Pandomics,” Kamya said, which turned out to be a bad choice in the middle of a pandemic. “Omics” is a microbiology term covering a swath of subspecialties like genomics, metabolomics and proteomics; “pan” implies the platform covers them all. The allusion to the furry klutzes China shares with favoured countries is a total coincidence, Kamya said (though Insilico has leaned into it with an android-looking panda mascot). “We are a global company,” she said. “I’m not going to say we have not been challenged. People think we’re a Chinese company or we’re affiliated with Russia, but the truth is we’re a global company, and we’ve managed so far to avoid getting tangled with geopolitical issues.” Get more from The Logic Sign up for a free trial of Canada's best business newsletter. But Zhavoronkov is Insilico’s founder and co-CEO, which makes this gathering in the Queen Elizabeth Hotel his party, and him the black-clad, Slavic-accented, slick-haired master of ceremonies on a riser. F ine, he says. I have 20 slides left, but I’ll skip a few and go fast. Buckle up. It’s not as though Zhavoronkov’s audience can’t appreciate the ride, even if it is sometimes a fever of logos and dense timelines and imaging methylation transcriptomics. The group includes people like Health Canada’s chief data officer, and its director general for rare diseases; senior officials from Innovation Canada; whizzes like the University of Toronto’s Alán Aspuru-Guzik and Steve Liu, a McGill University professor and associate member of Mila, Montreal’s AI research institute. https://thelogic.co/news/ai-based-drug-developer-insilico-starts-seriously-staffing-up-in-montreal/

Laurentian Bank reports profit down from system outage, cuts 2% of staff Ian Bickis The Canadian Press December 07, 2023 Laurentian Bank reports Q4 profit down Laurentian Bank of Canada said Thursday it was cutting staff and revamping its strategic plan as it works to move past a major system outage in September and the subsequent ousting of its chief executive. Éric Provost, who replaced Rania Llewellyn in the top job in October, said the bank is focused on improving customer relations, simplifying the organization and improving its technology. "I know that the past few months have been a challenging period for the bank with the conclusion of the strategic review and an outage of our mainframe," said Provost on an earnings call. "One thing is certain, that the status quo at Laurentian Bank is no longer an option." Provost's remarks come only months after a strategic review during which the bank explored various options, including a sale, only to decide that the best option was to continue with its existing strategy. Provost said the bank has already moved ahead with plans to cut about two per cent of staff this week, while it will be exploring a range of options as it charts a path forward. "Part of the rebuilding, we need to get back to the drawing board, make sure that we address a path of simplification." The revamp efforts come as the bank reported earnings of $30.6 million or 67 cents per diluted share for the quarter ended Oct. 31, down from a profit of $55.7 million or $1.26 per diluted share a year earlier. The bank says the results included a $5.3-million charge related to the mainframe outage and $15.9 million in restructuring and strategic-review related charges. Revenue for the quarter totalled $247.4 million, down from $257.1 million a year ago, while provisions for credit losses totalled $16.7 million for the quarter compared with $17.8 million in the fourth quarter of 2022. On an adjusted basis, Laurentian says it earned $1 per diluted share in its latest quarter, down from an adjusted profit of $1.31 per diluted share in the same quarter last year. Results were well below the $1.16 consensus and the $1.15 National Bank expected, said analyst Gabriel Dechaine in a note, with the miss in part because of the IT outage that led the bank to hold higher liquidity levels and refund service charges. He said that while the bank is guiding more stable results ahead, it will still face another severance charge next quarter, along with wider bank challenges. "Overall, we view LB as an increasingly challenged bank in an increasingly challenging macroeconomic and competitive environment," Dechaine said. Provost said on the call that he's aware of the difficulties ahead. "We have a lot of work ahead of us as we revamp our strategic plan and continue to implement our priorities of customer focus, simplifying the bank and making investments in our foundational technology." This report by The Canadian Press was first published Dec. 7, 2023. Companies in this story: (TSX:LB) Note to readers: This is a corrected story. A previous version incorrectly referred to a second strategic review at the bank. https://apple.news/AE2TIxDrOQNeFM29pup4Hxw

Ayoye

Même s'il y a qu'un seul soumissionnaire, celui-ci ai besoin de plus de temps pour préparer l'offre... ces délais supplémentaires peuvent être négociés (comme tout le reste).... rien d'anormal.

Les "pastilles" sont générés par le logiciel... il regarde les mots clefs dans le premier message habituellement... ceci permet aux membres en cliquant sur la pastille, de trouver d'autres sujets ayant la même pastille. image prise du premier message: Ceci dit, les pastilles peuvent être enlevés, modifiés, etc.

1177378343 trillion ... lets go return it. L'économie mondiale est de 100 trillion, je veux ben réparations ....

J’ai mal au cerveau en regardant les rues avez ZÉRO détritus ou quoi que ce soit. On dirait c’est photoshopper 💀💀

Ça va beaucoup plus vite que plusieurs pensaient, il faut littéralement enlever le point d'exclamation sur le vidéo que j'ai mis en ligne.... Le Vénézuela a déjà légiféré pour annexer la "nouvelle province", mise à jour la carte national officielle et masse ses troupes sur la frontières.

C'est pas juste les politiques d'immigration aveugle, c'est aussi les taxes et politiques enviro trop lourdes, contraignantes et rapides... je t'invite à lire cet article: https://www.politico.eu/article/far-right-giorgia-meloni-europe-swings-right-and-reshapes-the-eu ou ça: https://www.economist.com/international/2023/10/11/the-global-backlash-against-climate-policies-has-begun Tout n'est pas toujours rapporté dans nos médias ici, mais un évènement en particulier a été très médiatisé ici, la hausse de la taxe sur le carburant en France.... gilet jaunes et désordre civil pendant des mois. J'espère que tu t'en rappelles.

La tendance encore plus lourde dans le monde, c'est d'élire des gouvernements populiste qui vont annuler toutes ces mesures là. Les mesures pour limiter l'impact carbone, sont tellement rapides, tellement chères et peu efficaces que les gens débarquent en masse et n'y croient plus. Ce n'est pas une question d'être un négationniste de ce qui passe avec l'environnement, mais plutôt le fait que la population perçoit toutes ces mesures comme une autre façon de taxer et de limiter leur liberté économique. Et au final, rien ne s'est amélioré... au contraire. Je peux nommer beaucoup de pays qui ont basculé dans les derniers 12 mois dans le populisme, mais je suis sûr que tu le sais déjà si tu suis les nouvelles. Donc qu'est ce qui est mieux? Forcer dans la gorge de la population des pseudos-solutions qui ne fonctionnent pas, ou élire des gouvernements populistes qui risquent de foutre plus de bordel? Les routes sont utilisés pour le bien de 100% de la population, ta nourriture et ton énergie n'arrive pas par téléportation, surtout pas là où tu habites. Chaque citoyen profite de ce bien commun et doit payer sa part pour ces infra routières. C'est normal que la province, par le biais des taxes que tous* les citoyens paient, doit assumer l'entière facture. (Québec n'est pas une entité qui peut "imprimer" de l'argent par magie... c'est la somme des taxes de tous ses citoyens). Selon les chiffres de 2010, 34% des québécois utilisent régulièrement les TEC... je ne crois pas que ce chiffre à augmenté depuis, au contraire. https://statistique.quebec.ca/fr/produit/tableau/proportion-de-la-population-quebecoise-utilisant-regulierement-le-transport-en-commun-selon-certaines-caracteristiques-sociodemographiques-et-economiques-2010 100% = 31.5MM$ 34% = 15.4MM$ Qu'est ce qui coûte plus cher à l'état québécois d'après toi? *en réalité 40% des québécois ne paient aucuns taxes sur le revenu.

Ça sent la guerre en Amérique du Sud...

la presse republie la même chose aux 2 mois et tu les recopies ici, on a compris les 45 premières fois. Ces SUV paient leur sur-taxes déjà. As tu regarder le lien vers la SAAQ? Ils font amplement leur part. C’est pas la faute des automobilistes si les sociétés de transports sont mal gérées.

C’est complètement débile mental. Les grosses cylindrées paient déjà une surtaxe à l’immatriculation de plusieurs centaines de dollars par année…. Sans compter que les gros consommateurs d’essence paient en masse leur part de la taxe d’essence. Ça s’arrête où. Du gros journalisme de La Presse, zéro recherche. https://saaq.gouv.qc.ca/saaq/tarifs-amendes/immatriculation/cout-immatriculation-additionnel-vehicules-forte-cylindree

Ok d’accord. Mais c’est quand même 3 fois moins que avant le SRB. Maintenant que l’intersection est terminée, crois tu que l’achalandage va tripler?

Yes they do.... there's way less of them, but the one still open are busy. Actually cobblers should be encouraged, repair a shoe, better than throw it out

Non mais attends 25k vs 75k avant le SRB?!?!? (Je suppose c'est une moyenne journalière). C'est pas supposé augmenter la capacité?